On the stock market since 2003, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $77K a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 21 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.7M against $77K in annual sales.
The stock sits at $0.0007. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, RGRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RGRX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.